

**Listing of Claims**

No amendments are being made to the claims in the present Reply. This listing is being provided solely for the convenience of the Examiner.

**Listing of Claims:**

1-4. (Cancelled)

5. (Previously Presented) A method of treating diabetes with sulfonylurea secondary failure in a diabetic mammal with sulfonylurea secondary failure which comprises administering an effective amount of a dipeptidyl peptidase IV inhibitor to the mammal.

6. (Cancelled)

7. (Cancelled)

8. (Previously Presented) A method of promoting insulin secretion in a diabetic patient with sulfonylurea secondary failure which comprises administering an effective amount of a dipeptidyl peptidase IV inhibitor to the patient.

9. (Previously Presented) The method according to Claim 5 wherein the sulfonylurea secondary failure is ascribable to a sulfonylurea compound.

10. (Previously Presented) The method according to Claim 5 wherein the sulfonylurea secondary failure is ascribable to a fast-acting insulin secretagogue.

11. (Previously Presented) The method according to Claim 8 wherein the sulfonylurea secondary failure is ascribable to a sulfonylurea compound.

12. (Previously Presented) The method according to Claim 8 wherein the sulfonylurea secondary failure is ascribable to a fast-acting insulin secretagogue.